Matching articles for "carboplatin"
Issue 1733 · July 21, 2025
Penpulimab (Anniko) for Nasopharyngeal Carcinoma (online only)

Penpulimab-kcqx ( Anniko – Akeso Biopharma), a programmed death receptor-1 (PD-1)-blocking antibody, has been approved by the FDA for use in combination with cisplatin or carboplatin plus gemcitabine for…

Med Lett Drugs Ther. 2025 Jul 21; 67(1733):e122-3 doi:10.58347/tml.2025.1733k
Penpulimab-kcqx ( Anniko – Akeso Biopharma), a programmed death receptor-1 (PD-1)-blocking antibody, has been approved by the FDA for use in combination with cisplatin or carboplatin plus gemcitabine for first-line treatment of recurrent or metastatic nonkeratinizing nasopharyngeal carcinoma and for use as monotherapy for metastatic disease in adults with disease progression on or after platinum-based chemotherapy and at least one other prior line of therapy. Penpulimab is the second immune checkpoint inhibitor to be approved in the US for treatment of nasopharyngeal carcinoma; toripalimab (Loqtorzi) was approved in 2024.
Issue 1733 · July 21, 2025
Retifanlimab (Zynyz) for Anal Cancer (online only)

Retifanlimab-dlwr ( Zynyz – Incyte), a programmed death receptor-1 (PD-1)-blocking antibody, has been approved by the FDA for use in combination with carboplatin and paclitaxel for first-line treatment of…

Med Lett Drugs Ther. 2025 Jul 21; 67(1733):e126-7 doi:10.58347/tml.2025.1733m
Retifanlimab-dlwr ( Zynyz – Incyte), a programmed death receptor-1 (PD-1)-blocking antibody, has been approved by the FDA for use in combination with carboplatin and paclitaxel for first-line treatment of unresectable locally recurrent or metastatic squamous cell carcinoma of the anal canal (SCAC) and as monotherapy in patients who had disease progression or intolerance to platinum-based chemotherapy. The drug received accelerated approval for treatment of recurrent locally advanced or metastatic Merkel cell carcinoma in 2023.
Issue 1683 · August 21, 2023 Free
In Brief: A New Endometrial Cancer Indication for Dostarlimab (Jemperli) (online only)

The immune checkpoint inhibitor dostarlimab-gxly ( Jemperli – GSK) has been approved by the FDA for use in combination with carboplatin and paclitaxel for treatment of adults with mismatch repair deficient…

Med Lett Drugs Ther. 2023 Aug 21; 65(1683):e138 doi:10.58347/tml.2023.1683f
The immune checkpoint inhibitor dostarlimab-gxly ( Jemperli – GSK) has been approved by the FDA for use in combination with carboplatin and paclitaxel for treatment of adults with mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) primary advanced or recurrent endometrial cancer. Dostarlimab was recently granted regular approval for treatment of adults with dMMR recurrent or advanced endometrial cancer that progressed on or following a prior platinum-containing regimen in any setting and who are not candidates for curative surgery or radiation.
Issue 1537 · January 1, 2018 Free
In Brief: Pembrolizumab (Keytruda) for Cancers with Biomarkers (online only)

The immune checkpoint inhibitor pembrolizumab ( Keytruda – Merck), a programmed death receptor-1 (PD-1) inhibitor, has been granted accelerated approval by the FDA for use in adults and children who have…

Med Lett Drugs Ther. 2018 Jan 1; 60(1537):e8
The immune checkpoint inhibitor pembrolizumab ( Keytruda – Merck), a programmed death receptor-1 (PD-1) inhibitor, has been granted accelerated approval by the FDA for use in adults and children who have unresectable or metastatic microsatellite-instability-high (MSI-H) or mismatch-repair-deficient (dMMR) solid tumors that have progressed following treatment, and do not have any satisfactory alternative treatment options. For metastatic colorectal cancer, the indication is limited to tumors that have progressed following combination treatment with a fluoropyrimidine, oxaliplatin, and irinotecan. This is the first approval of a cancer drug based solely on the presence of certain biomarkers, regardless of the organ in which the cancer originated or the histology of the tumor. MSI-H and dMMR are markers for abnormalities in cancer cells that prevent DNA replication and postreplicative DNA repair. 1 These biomarkers are found most commonly in cancers of the endometrium, stomach, and colon. The incidence of MSI-H or dMMR in these tumors appears to be lower in advanced disease than in early-stage disease; about 5% of patients with metastatic colorectal cancer have MSI-H or dMMR tumors. 2 FDA approval was based on data from five unpublished, single-arm trials of pembrolizumab (summarized in the package insert) that included a total of 149 previously treated adults with various MSI-H or dMMR metastatic or unresectable tumors (90 patients had colorectal cancer). The overall objective response rate was 39.6% and the complete response rate was 7.4%. The median duration of response had not been reached by the end of the study; 78.0% of patients had a response duration of ≥6 months. Adverse reactions, including immune-mediated effects, were similar to those reported previously with pembrolizumab. The recommended adult dosage of pembrolizumab for this indication is 200 mg IV (2 mg/kg up to a maximum of 200 mg for children) every 3 weeks for a maximum of 24 months. The cost for one adult dose is about $9162. 3 Pembrolizumab was previously approved for treatment of unresectable or metastatic melanoma, 4 metastatic non-small cell lung cancer (NSCLC), including nonsquamous NSCLC in combination with pemetrexed and carboplatin, 5 recurrent or metastatic head and neck squamous cell carcinoma, refractory classical Hodgkin lymphoma, locally advanced or metastatic urothelial carcinoma, 6 and recurrent locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma. A Copija et al. Clinical significance and prognostic relevance of microsatellite instability in sporadic colorectal cancer patients. Int J Mol Sci 2017 Jan 6 (epub). S Lemery et al. First FDA approval agnostic of cancer site - when a biomarker defines the indication. N Engl J Med 2017; 377:1409. Approximate WAC. WAC represents a published catalogue or list price and may not represent an actual transactional price. Source: AnalySource® Monthly. December 5, 2017. Reprinted with permission by First Databank, Inc. All rights reserved. ©2017. www. fdbhealth.com/policies/drug-pricing-policy. Pembrolizumab (Keytruda) for metastatic melanoma. Med Lett Drugs Ther 2014; 56: e114. Pembrolizumab (Keytruda) for first-line treatment of metastatic NSCLC. Med Lett Drugs Ther 2017; 59:22. Three more immune checkpoint inhibitors for advanced bladder cancer. Med Lett Drugs Ther 2017; 59:e202. Download complete U.S. English article
Issue 29 · January 1, 2005
Drugs for Breast Cancer

In addition to surgery and radiation therapy, a variety of drugs are used both singly and in combination to treat breast cancer. This article summarizes the principles of adjuvant therapy and treatment for…

Treat Guidel Med Lett. 2005 Jan; 3(29):1-6
In addition to surgery and radiation therapy, a variety of drugs are used both singly and in combination to treat breast cancer. This article summarizes the principles of adjuvant therapy and treatment for metastatic disease. A summary of individual drugs and their adverse effects begins on page 3.
Issue 1180 · April 12, 2004
Pemetrexed (Alimta) for Mesothelioma

The combination of pemetrexed ( Alimta - Lilly) and cisplatin is the first chemotherapy regimen approved by the FDA for treatment of malignant pleural mesothelioma. This uncommon malignancy, which has been…

Med Lett Drugs Ther. 2004 Apr 12; 46(1180):31-2
The combination of pemetrexed ( Alimta - Lilly) and cisplatin is the first chemotherapy regimen approved by the FDA for treatment of malignant pleural mesothelioma. This uncommon malignancy, which has been linked to asbestos exposure, was previously considered unresponsive to chemotherapy, with a median survival of 6-8 months from diagnosis (VW Rusch, J Clin Oncol 2003; 21:2629).
Issue 1179 · March 29, 2004
Palonosetron (Aloxi) for Prevention of Nausea and Vomiting Due to Cancer Chemotherapy

Palonosetron ( Aloxi - Helsinn Healthcare SA, Switzerland, distributed in the US by MGI Pharma) is the fourth serotonin (5-HT 3 ) receptor antagonist to become available in the US and the first to be approved…

Med Lett Drugs Ther. 2004 Mar 29; 46(1179):27-8
Palonosetron ( Aloxi - Helsinn Healthcare SA, Switzerland, distributed in the US by MGI Pharma) is the fourth serotonin (5-HT 3 ) receptor antagonist to become available in the US and the first to be approved by the FDA for prevention of both acute and delayed nausea and vomiting due to moderately emetogenic cancer chemotherapy. It is also approved for prevention of acute nausea and vomiting due to highly emetogenic drugs such as cisplatin ( Platinol , and others). Aprepitant ( Emend ), a substance P/neurokinin-1 receptor antagonist, was approved last year for use with a 5-HT 3 antagonist and dexamethasone to prevent both acute and delayed nausea and vomiting due to highly emetogenic drugs ( Medical Letter 2003; 45:62 ).
Issue 1162 · August 4, 2003
Aprepitant (Emend) for Prevention of Nausea and Vomiting Due to Cancer Chemotherapy

Aprepitant ( Emend - Merck), the first substance P/neurokinin 1 (NK 1 ) receptor antagonist to be approved by the FDA, is now available for oral use with corticosteroids and selective serotonin (5-HT 3 )…

Med Lett Drugs Ther. 2003 Aug 4; 45(1162):62-3
Aprepitant ( Emend - Merck), the first substance P/neurokinin 1 (NK 1 ) receptor antagonist to be approved by the FDA, is now available for oral use with corticosteroids and selective serotonin (5-HT 3 ) receptor antagonists to prevent nausea and vomiting caused by highly emetogenic anticancer drugs such as cisplatin.
Issue 7 · March 1, 2003
Drugs of Choice for Cancer

The tables in this article list drugs used for treatment of cancer in the USA and Canada and their major adverse effects. The choice of drugs in Table I is based on the opinions of Medical Letter consultants.…

Treat Guidel Med Lett. 2003 Mar; 1(7):41-52
The tables in this article list drugs used for treatment of cancer in the USA and Canada and their major adverse effects. The choice of drugs in Table I is based on the opinions of Medical Letter consultants. Some drugs are listed for indications for which they have not been approved by the US Food and Drug Administration. In some cases, such as elderly patients or those with many co-morbid illnesses, the regimen of choice might not be suitable. For many of the cancers listed, surgery and/or radiation therapy may be the treatment of choice or may also be part of the management. Anticancer drugs and their adverse effects are listed in Table II on page 46. A partial list of brand names appears on page 52.
Issue 1148 · January 20, 2003
Oxaliplatin (Eloxatin) for Advanced Colon Cancer

Oxaliplatin ( Eloxatin -Sanofi-Synthelabo) has been approved by the FDA for use in combination with fluorouracil (5-FU; Adrucil , and others) and leucovorin (LV; Wellcovorin ) for patients with metastatic…

Med Lett Drugs Ther. 2003 Jan 20; 45(1148):7-8
Oxaliplatin ( Eloxatin -Sanofi-Synthelabo) has been approved by the FDA for use in combination with fluorouracil (5-FU; Adrucil , and others) and leucovorin (LV; Wellcovorin ) for patients with metastatic colorectal cancer whose disease has recurred or progressed despite treatment with 5-FU/LV plus irinotecan ( Camptosar - Medical Letter 1997; 39:8).
Issue 1087 · September 18, 2000
Drugs of Choice For Cancer Chemotherapy (combined issue 1087-1088)

The tables in this article list drugs used for treatment of cancer in the USA and Canada. The choices of drugs in Table 1 is based on the opinions of Medical Letter consultants. Some drugs are listed for…

Med Lett Drugs Ther. 2000 Sep 18; 42(1087):83-92
The tables in this article list drugs used for treatment of cancer in the USA and Canada. The choices of drugs in Table 1 is based on the opinions of Medical Letter consultants. Some drugs are listed for indications for which they have not been approved by the US Food and Drug Administration. For many of the cancers listed, surgery and/or radiation therapy are also part of the management of the disease.
Issue 996 · March 14, 1997
Drugs of Choice for Cancer Chemotherapy

The tables that follow list drugs used for treatment of cancer in the USA and Canada and their major adverse effects. The choice of drugs in Table I is based on the opinions of Medical Letter consultants. Some…

Med Lett Drugs Ther. 1997 Mar 14; 39(996):21-8
The tables that follow list drugs used for treatment of cancer in the USA and Canada and their major adverse effects. The choice of drugs in Table I is based on the opinions of Medical Letter consultants. Some drugs are listed for indications for which they have not been approved by the US Food and Drug Administration. For most of the cancers listed, surgery and/or radiation therapy are part of the management of the disease. Anticancer drugs and their adverse effects are listed in Table II.
Issue 986 · October 25, 1996
Topotecan Hydrochloride for Metastatic Ovarian Cancer

Topotecan hydrochloride ( Hycamtin - SmithKline Beecham) was recently approved by the U.S. Food and Drug Administration for parenteral use as a single agent in patients with metastatic ovarian cancer…

Med Lett Drugs Ther. 1996 Oct 25; 38(986):96-7
Topotecan hydrochloride ( Hycamtin - SmithKline Beecham) was recently approved by the U.S. Food and Drug Administration for parenteral use as a single agent in patients with metastatic ovarian cancer refractory to other drugs. Initial treatment for metastatic ovarian cancer usually consists of cisplatin ( Platinol ) or carboplatin ( Paraplatin ) plus paclitaxel ( Taxol ) or cyclophosphamide ( Cytoxan , and others).
Issue 912 · December 24, 1993
Drugs for Vomiting Caused by Cancer Chemotherapy

Several currently available antiemetic drugs can prevent vomiting caused by cancer chemotherapy. Anticancer drugs that cause vomiting are listed in the table below.

Med Lett Drugs Ther. 1993 Dec 24; 35(912):124-6
Several currently available antiemetic drugs can prevent vomiting caused by cancer chemotherapy. Anticancer drugs that cause vomiting are listed in the table below.
Issue 896 · May 14, 1993
Paclitaxel (Taxol) for Ovarian Cancer

Paclitaxel ( Taxol - Bristol-Myers Squibb) is now available in the USA for treatment of metastatic ovarian cancer refractory to other drugs. The new drug is a natural product extracted in small amounts from…

Med Lett Drugs Ther. 1993 May 14; 35(896):39-40
Paclitaxel ( Taxol - Bristol-Myers Squibb) is now available in the USA for treatment of metastatic ovarian cancer refractory to other drugs. The new drug is a natural product extracted in small amounts from the inner bark of the Western yew tree found mainly in the Pacific northwest ( Taxus brevifolia ). Efforts to synthesize the drug have been unsuccessful to date, but a semi-synthetic product (taxotere) prepared from the needles of European yews has shown some promise (R Pazdur et al, J Natl Cancer Inst, 89:1781, 1992), and a fungus ( Taxomyces andreanae ) growing on the Pacific yew was recently found to produce paclitaxel even after removal from the tree (A Stierle et al, Science, 260:214, April 9, 1993). In any case, supply of the drug is currently keeping up with demand.
Issue 877 · August 21, 1992
Bone Marrow Transplants for Malignant Diseases

Intensive chemotherapy, with or without total body radiation, followed by bone marrow transplantation is now widely used in the treatment of malignant diseases. The drugs and radiation needed to try to…

Med Lett Drugs Ther. 1992 Aug 21; 34(877):79-80
Intensive chemotherapy, with or without total body radiation, followed by bone marrow transplantation is now widely used in the treatment of malignant diseases. The drugs and radiation needed to try to eradicate the malignancy unavoidably destroy the bone marrow; intravenous infusion of bone marrow cells restores the marrow by repopulating it. Diseases for which bone marrow transplantation has been used include the leukemias and lymphomas, breast cancer, neuroblastoma, ovarian cancer, germ cell tumors, melanoma, multiple myeloma, and malignant gliomas (NC Gorin, Am J Clin On-col, 14 suppl 1:S5, 1991; Medical Letter, 33:39, 1991; G Gahrton et al, N Engl J Med, 325:1267, 1991).
Issue 800 · September 8, 1989
Carboplatin

Carboplatin ( Paraplatin - Bristol-Myers), a cytotoxic platinum-containing drug chemically related to cisplatin ( Platinol ), was recently approved by the US Food and Drug Administration (FDA) for palliative…

Med Lett Drugs Ther. 1989 Sep 8; 31(800):83-4
Carboplatin ( Paraplatin - Bristol-Myers), a cytotoxic platinum-containing drug chemically related to cisplatin ( Platinol ), was recently approved by the US Food and Drug Administration (FDA) for palliative treatment of patients with recurrent ovarian cancer, including those previously treated with cisplatin.